All Duke Cancer Institute articles
-
NewsGroundbreaking clinical trial evaluates oncolytic virus for non-small cell lung cancer
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer, using a novel oncolytic virus, MEM-288, in combination with the immune checkpoint inhibitor nivolumab.
